CoChat

Serum tumor markers for the diagnosis of cholangiocarcinoma in primary sclerosing cholangitis

The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.

Abstract

Background/aims The diagnosis of cholangiocarcinoma in primary sclerosing cholangitis (PSC), even with the use of current imaging techniques and brush cytology, is difficult and particularly important in patients being assessed for liver transplantation. This study investigated the accuracy of serum levels of a combination of the tumor markers carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9) in the diagnosis of cholangiocarcinoma in patients with PSC.Methods Seventy-four patients with PSC were studied. Fifteen patients had tumors (11 occult on imaging), 22 had severe PSC that necessitated transplantation (with explanted liver known to be free of tumor), and 37 patients had stable PSC.Results An index of the two serum tumor markers [using the formula CA19-9 + (CEA x 40)] gave an accuracy of 86% in diagnosis of cholangiocarcinoma, with 10 of the 15 cases of cholangiocarcinoma having an increased value compared with none in a group of 22 comparable cases with no tumor. In addition, 6 of the 11 patients with occult tumors had abnormal values. Ultrasonography, computerized tomographic scanning, and endoscopic retrograde cholangiopancreatography were poor predictors of the presence of tumor.Conclusions A combination of serum tumor markers will identify most occult tumors and will improve selection of appropriate cases for orthotopic liver transplantation.

Overview

Integrity signals

Registry

Crossref · 10.1016/0016-5085(95)90462-x

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 29 references

Research works printed but not linked: 3

  1. Steinberg, 1990, The clinical utility of the CA19-9 tumour associated antigen, Am J Gastroenterol, 85, 350
  2. Safi, 1986, Ca19-9 and pancreatic adenocarcinoma, Cancer, 57, 779, 10.1002/1097-0142(19860215)57:4<779::AID-CNCR2820570417>3.0.CO;2-C · doi:10.1002/1097-0142(19860215)57:4<779::aid-cncr2820570417>3.0.co;2-c
  3. Ramage, 1989, Are serum values of tumour markers useful clinically in predicting the presence of pancreatic malignancy (abstr)?, Gut, 30, A1507

Cited by

See all 279

Metadata

Authors
Ramage, J. K., Donaghy, A., Farrant, J. M., Iorns, R., & Williams, R.
Affiliations
King's College Hospital (GB)
Venue
Gastroenterology
Publisher
Elsevier BV
Published
1995-03
Volume
108
Issue
3
Pages
865-869
ISSN
0016-5085 (ISSN-L)
OpenAlex
W2129563967
Cited by
279
References
28
Citations by year
2026: 4 · 2025: 3 · 2024: 4 · 2023: 8 · 2022: 5 · 2021: 6 · 2019: 5 · 2018: 5 · 2017: 8 · 2016: 9 · 2015: 9 · 2014: 8 · 2013: 5 · 2012: 13
FWCI
10.33
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • Gastroenterology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Surgery › Cholangiocarcinoma and Gallbladder Cancer Studies
  • Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
  • Health Sciences › Medicine › Surgery › Pediatric Hepatobiliary Diseases and Treatments
Keywords
cholangiocarcinoma, primary sclerosing cholangitis, serum tumor markers, carcinoembryonic antigen, CA19-9, occult malignancy, liver transplantation, tumor diagnosis, diagnostic accuracy
MeSH terms
Adult, Bile Duct Neoplasms, Bile Ducts, Intrahepatic, Carcinoembryonic Antigen, Cholangiopancreatography, Endoscopic Retrograde, Female, Humans, Male, Middle Aged, Sensitivity and Specificity, Biomarkers, Tumor, Ultrasonography, Cholangitis, Sclerosing, Antigens, Tumor-Associated, Carbohydrate, Cholangiocarcinoma

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Serum tumor markers for the diagnosis of cholangiocarcinoma in primary sclerosing cholangitis. https://app.cochat.ai/papers/10.1016/0016-5085(95)90462-x
The paper
Ramage, J. K., Donaghy, A., Farrant, J. M., Iorns, R., & Williams, R. (1995). Serum tumor markers for the diagnosis of cholangiocarcinoma in primary sclerosing cholangitis. Gastroenterology. https://doi.org/10.1016/0016-5085(95)90462-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.